The Centers for Medicare & Medicaid Services (CMS) Establishes Coding and Payment for Eustachian Tube Balloon Dilation
May 22 2017 - 4:03PM
Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company
focused on delivering superior patient and physician experiences
through products designed for the minimally invasive treatment of
chronic and recurrent sinusitis patients, as well as the treatment
of patients with Eustachian tube dysfunction, today announced that
the CMS has established a unique billing code and payment for
endoscopic balloon dilation to treat Eustachian tube dysfunction
(ETD). The code, C9745, will become effective July 1, 2017 and will
facilitate payment for the outpatient treatment of ETD using
balloon dilation in hospitals and ambulatory surgery centers (ASC).
“We are pleased by CMS’s decision to establish payment for
endoscopic balloon dilation to treat ETD,” said Robert White,
President and Chief Executive Officer of Entellus Medical. “The new
payment code is associated with a national average payment of
$4,130 in the hospital outpatient department, a payment that is
consistent with those made for balloon dilations of the various
sinus cavities in patients with chronic and recurring acute
sinusitis. With the creation of a unique code and payment that is
intended to cover the cost of the device and procedure, CMS
removed one of the biggest obstacles to providers who seek to bring
this innovative new treatment to their patients.”
C codes are unique temporary pricing codes that were initially
established by CMS for the Hospital Outpatient Prospective Payment
System (HOPPS) to promote the adoption of new medical technology
that otherwise had no codes to facilitate payment. These
payment codes are typically available for two to three years and
Entellus believes, based on long-standing CMS policy, that billing
code and payment for endoscopic balloon dilation to treat ETD will
be effective through the end of 2019. C codes are used on Medicare
HOPPS claims but may also be recognized on claims from other
providers or by other payment systems.
About Entellus Medical, Inc.
Entellus Medical is a medical technology company focused on
delivering superior patient and physician experiences through
products designed for the minimally invasive treatment of
patients. Entellus products are used for the treatment of
adult and pediatric patients with chronic and recurrent sinusitis,
as well as adult patients with persistent Eustachian tube
dysfunction. The Entellus Medical platform of products
provides effective and easy-to-use solutions intended to help
simplify everything from diagnosis and patient selection, to
complex case revisions and post-operative care. Entellus Medical’s
core product lines, XprESS™ ENT Dilation System, MiniFESS™ Surgical
Instruments, XeroGel Nasal Dressing and FocESS™ Imaging &
Navigation, combine to enable ENT physicians to conveniently and
comfortably perform a broad range of procedures in the office and
simplify treatment based in the operating room. Entellus Medical is
committed to broadening its product portfolio with high-quality and
purposeful innovations for the global ENT market.
Contact: Lynn Pieper Lewis
415-937-5402
ir@entellusmedical.com
ENTELLUS MEDICAL INC (NASDAQ:ENTL)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENTELLUS MEDICAL INC (NASDAQ:ENTL)
Historical Stock Chart
From Jul 2023 to Jul 2024